Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

2.630 +0.320 (+13.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
From The Rosen Law Firm PA
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Neumora Therapeutics, Inc. – NMRA
From The Rosen Law Firm, P.A.
Via Business Wire
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
From DJS Law Group
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Crude Oil Surges 2%; Tesla Shares Plummet
 
Via Benzinga
Nasdaq Dips Over 100 Points; Unity Software Shares Jump
 
Via Benzinga
Dow Surges Over 300 Points; US Initial Jobless Claims Decline
 
Via Benzinga
Topics Stocks
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
The company said it plans to investigate a positive signal from female patients. 
Via Investor's Business Daily
Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and updates are anticipated. 
Via Benzinga
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
From Neumora Therapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in November
From Neumora Therapeutics, Inc.
Via GlobeNewswire
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Neumora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET 
From Neumora Therapeutics, Inc.
Via GlobeNewswire
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
From Neumora Therapeutics, Inc.
Via GlobeNewswire
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
From Neumora Therapeutics, Inc.
Via GlobeNewswire
Neumora Therapeutics to Participate in Upcoming Conferences in May
From Neumora Therapeutics, Inc.
Via GlobeNewswire
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.